Precocious Puberty
Precocious Puberty
Precocious Puberty
Precocious Puberty
Andrew Muir, MD*
Objectives After completing this article, readers should be able to:
Introduction
Although precocious puberty has standard clinical definitions and diagnostic tests are
improving, the management of children who have signs of early puberty has become more
complex in some ways during the last decade than ever before. This review illustrates how
an understanding of the anatomy and physiology of puberty forms the foundation for
managing children who experience puberty early.
Case History
A 4-year-old female has developed pubic hair in the past 3 months and has had an adult body
odor for 6 months. She is otherwise healthy and has no pertinent findings on medical and
surgical history. Her height and weight are just above the 97th percentile for age, and her
physical examination reveals Sexual Maturity Rating (SMR) 2 breast and pubic hair
development.
Definitions
By convention, normal puberty begins between ages 8 and 12 years in girls and between
9 and 14 years in boys. The lower ages of normal pubertal onset recently have been
challenged, but a consensus to accept puberty among younger children as being normal
without diagnostic evaluation has not been reached. Criteria for defining the five stages of
puberty in boys and girls, proposed by Marshall and Tanner in 1969 and 1970, remain the
standard (Fig. 1).
Thelarche (the -lar’ke ), the onset of female breast development, is characterized by
tender nodules of firm tissue centered on the areolae, which usually are appreciable by
palpation before they are by visual inspection. In overweight girls, palpation is essential to
distinguish sex steroid-dependent breast (firm, nodular, and possibly tender) from adipose
tissue (soft, homogeneous, and nontender). Adrenarche (ad‘ren-ar’ke ) is the onset of
androgen-dependent signs of puberty (pubic hair, acne, and adult body odor). In females,
adrenarche is the result of adrenocortical activity. In males, either adrenal or gonadal
maturation can prompt adrenarche. Some sources refer to adrenarche as pubarche
(pu-bar’ke ). Menarche (mĕ-nar’ke ) is the onset of menstruation.
Epidemiology
The estimated incidence of precocious puberty in the United States is 0.01% to 0.05% per
year. It is 4 to10 times more frequent in females than in males and more common among
African-American than among Caucasian children. A century-long secular trend reduced
the age of menarche by about 0.3 years per decade until the 1960s. At that point, the rate
of decline in developed countries slowed or even stopped. In the United States, the mean
Figure 1. Stages of normal puberty described by Marshall and Tanner. A. The normal progression of male puberty. Sexual Maturity
Rating (SMR) 1 (not shown) is prepubertal, with testicular volumes less than 4 mL, a thick and rugated scrotum, and an immature
penis. By SMR 2, coarse, sex steroid-dependent hair has appeared on the pubis, but it is sparse and does not typically meet in the
midline. The penis remains immature, but scrotal thinning and testicular enlargement have begun. SMR 3 is characterized by pubic
hair meeting at the midline and the start of penis growth, predominantly in length. At SMR 4, the pubic hair growth is dense and
continuous, but has not reached a full adult pattern. The penis has enlarged in both length and circumference. SMR 5 is that of full
adult development. B. Normal pubic hair development of the female. The descriptions are similar to those for male pubic hair growth.
C. Normal progression of breast development. Stage 1 is the normal prepubertal state. Tender “buds” are felt and seen at stage 2,
and stage 3 is characterized by further development of breast tissue well beyond the areolar diameter and incomplete nipple
development. Stage 4 is easily recognized by secondary elevation of the areola above the contour of the breast, and by stage 5, this
areoloar elevation recedes to the plane of the surrounding breast.
age of menarche in Caucasians is near 12.7 years and in among some 17,000 healthy American children were
African-Americans is about 12.2 years (Table 1). The age 10.0 and 8.9 years for Caucasians and African-
of adrenarche in females is also race-dependent. The Americans, respectively. These ages were about 6 to 12
mean age of adrenarche in African-American girls is months lower than those reported a decade earlier. More
approximately 8.8 years compared with about 10.5 years surprisingly, a significant number of girls had thelarche
in Caucasian girls. In a 1997 report, the ages of thelarche during or before their seventh year. Some of these cases
identified best by high concentrations of the substrate for gressive central lesion, such as a hamartoma, usually is
the enzyme that is deficient. For example, 21-hydroxylase treated medically. Many children who have central pre-
deficiency is diagnosed by determining the serum 17- cocious puberty require treatment solely to delay addi-
hydroxyprogesterone concentration (Fig. 4). Random tional maturation. Clinical features suggesting that med-
measures of testosterone or estradiol are helpful for de- ical intervention to arrest central precocious puberty will
tecting gonadal steroid production. Advanced bone age, benefit the patient are male sex, age younger than 6 years,
especially if it has progressed beyond the height age, skeletal age advancing more rapidly than height age, and
serves as a nonspecific biomarker of abnormal sex steroid psychosocial disturbances (eg, menses will be arrested).
production. Among children who have idiopathic central GnRH agonist (eg, leuprolide) therapy is the most effec-
precocious puberty, bone age helps determine whether tive medical therapy available for central precocious pu-
treatment to stop additional development will be of berty. Tonic stimulation of the pituitary gland results in a
value. short period of pubertal stimulation, followed by down-
Because normal pituitary gland secretion of gonado- regulation of GnRH receptors and reduced gonadotro-
tropins is pulsatile, randomly obtained serum samples do pin synthesis. Although antagonists to GnRH (eg, cetro-
not reliably contain enough LH and FSH to permit relix, ganirelix) are not yet approved for use in precocious
traditional assays to diagnose the onset of puberty. Al- puberty, they promise to suppress puberty without the
though today’s most sensitive gonadotropin assays may initial gonadotropin stimulation seen with current
be able to distinguish between basal gonadotropin levels agents.
of prepubertal and pubertal children, most commercial The management of autonomous gonadal steroid se-
gonadotropin assays do not. Therefore, definitive dem- cretion in McCune-Albright syndrome and familial male-
onstration of an activated central
axis driving early puberty usually
The
requires stimulation testing with
exogenous GnRH. A single injec-
tion of GnRH will not increase
the serum gonadotropin concen-
demonstration of central precocious
trations in children who have a puberty should prompt a magnetic resonance
quiescent central pubertal axis (ie,
prepubertal or precocious puberty
study of the brain. . . .
from noncentral dysfunction).
Once the hypothalamic-pituitary
axis has become active, however, the injection causes a limited precocious puberty can be difficult. Medications
rise of FSH in early puberty, and increased LH release is to block: a) steroid production (eg, ketoconazole), b)
the most specific indicator of central puberty. The dem- 5-alpha reductase activity (eg, finasteride), c) steroid
onstration of central precocious puberty by GnRH test- receptors (eg, flutamide, spironolactone), and d) aro-
ing should prompt a magnetic resonance study of the matase activity (eg, testolactone, anastrozole) have been
brain with high-resolution imaging of the hypothalamus suggested, but formal trials are limited.
and pituitary gland. Children who have severe brain dysfunction and cen-
tral precocious puberty present special ethical concerns.
Management GnRH therapy may reduce behavioral problems and
Although general pediatricians may follow children who provide effective contraception. Therefore, it may be
have premature adrenarche or thelarche, initial evalua- tempting to offer this treatment to children who have
tion and management of precocious puberty often re- limited cognitive abilities and multiple special care needs.
quires subspecialty consultation. When a primary cause Reduced bone mineral density, eunuchoid growth, and
of precocious puberty can be identified, treatment of that ethical considerations arising from “chemical castra-
condition is paramount. Judgment is required to deter- tion,” however, are important disadvantages that must
mine whether central precocious puberty requires inter- be considered.
vention. Whereas some intracerebral tumors that cause Adrenocortical steroid production of androgens can
early puberty may require surgery for complete resection be controlled with glucocorticoid replacement in pa-
or preservation of normal cerebral function, other tu- tients who have CAH. This treatment, however, may be
mors (eg, germinoma) may be radiosensitive. A nonpro- ill advised for children who have late-onset forms of
21-hydroxylase deficiency and who are able to mount a observation or should be referred to a subspecialist for
normal glucocorticoid response to stress and predicted evaluation and treatment.
to have a normal final height. The risk of iatrogenic
adrenocortical suppression may outweigh any benefits
that treated children may accrue from chronic glucocor-
Suggested Reading
ticoid therapy.
Chalumeau M, Charalambos G, Hadjiathanasiou MD, et al. Select-
ing girls with precocious puberty for brain imaging: validation of
Prognosis European evidence-based diagnosis rule. J Pediatr. 2003;143:
The cause of precocious puberty determines the progno- 445– 450
sis. In most cases, central precocious puberty is arrested Denburg MR, Silfen ME, Manibo AM, et al. Insulin sensitivity and the
by adequate treatment with GnRH agonists. Menses insulin-like growth factor system in prepubertal boys with prema-
ture adrenarche. J Clin Endocrionol Metab. 2002;87:5704 –5709
stop, although a single period may occur 2 weeks after
Dungan HM, Clifton DK, Steiner RA. Kisspeptin neurons as cen-
therapy has been started. Breast, pubic hair, testicular, tral processors in the regulation of gonadotropin-releasing hor-
and phallus growth stop and often regress. Skeletal mone secretion. Endocrinology. 2006;147:1154 –1158
growth and maturation slow to age-appropriate rates. Kaplowitz PB, Oberfield SE. Reexamination of the age limit for
Serum testosterone or estradiol concentrations fall to defining when puberty is precocious in girls in the United States:
prepubertal levels, and GnRH infusions induce insignif- implications for evaluation and treatment. Drug and Therapeu-
tics and Executive Committees of the Lawson Wilkins Pediatric
icant changes in serum LH or FSH concentrations. Apart Endocrine Society. Pediatrics. 1999;104:936 –941
from the immediate benefits of GnRH agonist therapy, Klein KO, Barnes KM, Jones JV, et al. Increased final height in
final height in children who have central precocious precocious puberty after long-term treatment with LHRH ago-
puberty may increase by 8 to 12 cm compared with the nists: the National Institutes of Health experience. J Clin Endo-
crinol Metab. 2001;86:4711– 4716
heights of children diagnosed as having the same condi-
Marshall WA, Tanner JM. Variations in pattern of pubertal changes
tion before therapy was available. Earlier treatment is in girls. Arch Dis Child. 1969;44:291–303
associated with improved final height. The combined use Marshall WA, Tanner JM. Variations in pattern of pubertal changes
of growth hormone and GnRH agonists is controversial, in boys. Arch Dis Child. 1970;45:13–23
but may allow more growth in children who are particu- Midyett LK, Moore WV, Jacobson JD. Are pubertal changes in girls
before age 8 benign? Pediatrics. 2003;111:47–51
larly short. Once treatment has been stopped, puberty
Parent A-S, Teilmann G, Juul A, et al. The timing of normal puberty
usually resumes and progresses at a normal rate. and the age limits of sexual precocity: variations around the
world, secular trends, and changes after migration. Endocrine
Summary Rev. 2003;24:668 – 693
General pediatricians must be able to distinguish chil- Pucarelli I, Segni M, Ortore M, et al. Effects of combined
dren who are growing normally from those who are not. gonadotropin-releasing hormone agonist and growth hormone
therapy on adult height in precocious puberty: a further contri-
An understanding of the regulation and effects of sex bution. J Pediatr Endocrinol Metab. 2003;16:1005–1010
steroid production allows clinicians to determine Terasawa EI, Fernandez DL. Neurobiological mechanisms of the
whether a child who has precocious puberty requires onset of puberty in primates. Endocrine Rev. 2001;22:111–151
PIR Quiz
Quiz also available online at www.pedsinreview.org.
6. An 8-year-old African-American girl has recently developed pubic hair and adult body odor. She also has
scattered comedones and papules on her cheeks and forehead. On examination, her sexual maturity rating
(SMR) for pubic hair is 3. SMR for breast tissue is 1. Her linear growth velocity continues along the
percentile established by age 2 years. The most appropriate conclusion is that she:
A. Has been exposed to a large dose of exogenous estrogen.
B. Is experiencing normal adrenarche.
C. Requires immediate evaluation for a masculinizing tumor.
D. Will have elevated concentrations of thyroid-stimulating hormone (TSH).
E. Will have pubertal concentrations of follicle-stimulating hormone (FSH).
7. A 2-year-old Caucasian girl has had stable SMR stage 3 breast development for the past 9 months. Her
linear growth velocity has remained at the 75th percentile since age 1 year. The remainder of her
examination findings are normal. The most appropriate conclusion is that she:
A. Has a reduced risk for developing central precocious puberty compared with other girls of the same
age who have no breast development.
B. Has been exposed to a large dose of exogenous estrogen.
C. Is experiencing benign premature thelarche.
D. Must be evaluated for precocious puberty now.
E. Needs suppressive doses of gonadotropin-releasing hormone (GnRH) to prevent short stature.
8. An 8-year-old boy has recently experienced accelerated statural growth, impressive muscular development,
and enlargement of his phallus. His testicles are symmetric, each having a volume of 3 mL. The most
appropriate conclusion is that he:
A. Is undergoing normal puberty.
B. Likely has a human chorionic gonadotropin-producing tumor.
C. Likely has a very elevated concentration of dehydroepiandrosterone sulfate (DHEA-S).
D. Will have pubertal concentrations of serum leutinizing hormone (LH).
E. Will show an impressive increase in FSH in response to an injection of GnRH.
9. An 8-year-old boy has recently experienced accelerated statural growth, impressive muscular development,
and enlargement of his phallus. His testicles are symmetric, and each has a volume of 8 mL. An injection
of GnRH results in increased LH release. The most appropriate next step is:
A. Bone age studies of the wrist.
B. Magnetic resonance imaging of the brain and pituitary gland.
C. Serum DHEA-S measurement.
D. Serum 17-hydroxyprogesterone measurement.
E. Serum testosterone measurement.
10. An 8-year-old boy of normal intelligence has been diagnosed with idiopathic central precocious puberty.
Time-limited treatment with the GnRH agonist leuprolide most likely will:
A. Increase adult stature compared with no treatment.
B. Increase the risk of osteoporosis.
C. Produce irreversible gynecomastia.
D. Produce permanent chemical castration.
E. Selectively diminish expected adult phallus size.
Updated Information & including high resolution figures, can be found at:
Services http://pedsinreview.aappublications.org/content/27/10/373
References This article cites 11 articles, 4 of which you can access for free at:
http://pedsinreview.aappublications.org/content/27/10/373#BIBL
Subspecialty Collections This article, along with others on similar topics, appears in the
following collection(s):
Developmental/Behavioral Issues
http://pedsinreview.aappublications.org/cgi/collection/development:b
ehavioral_issues_sub
Endocrinology
http://pedsinreview.aappublications.org/cgi/collection/endocrinology
_sub
Puberty
http://pedsinreview.aappublications.org/cgi/collection/puberty_sub
Adolescent Health/Medicine
http://pedsinreview.aappublications.org/cgi/collection/adolescent_he
alth:medicine_sub
Permissions & Licensing Information about reproducing this article in parts (figures, tables) or
in its entirety can be found online at:
http://pedsinreview.aappublications.org/site/misc/Permissions.xhtml
Reprints Information about ordering reprints can be found online:
http://pedsinreview.aappublications.org/site/misc/reprints.xhtml
Downloaded from http://pedsinreview.aappublications.org/ at UCSF Kalmanovitz Library & CKM on December 6, 2014
Precocious Puberty
Andrew Muir
Pediatrics in Review 2006;27;373
DOI: 10.1542/pir.27-10-373
The online version of this article, along with updated information and services, is
located on the World Wide Web at:
http://pedsinreview.aappublications.org/content/27/10/373
Pediatrics in Review is the official journal of the American Academy of Pediatrics. A monthly
publication, it has been published continuously since 1979. Pediatrics in Review is owned,
published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point
Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2006 by the American Academy of
Pediatrics. All rights reserved. Print ISSN: 0191-9601.
Downloaded from http://pedsinreview.aappublications.org/ at UCSF Kalmanovitz Library & CKM on December 6, 2014